BLASINGLE-USEVIAL
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
6/8 — Strong
ACTIMMUNE (interferon gamma-1b) by Amgen is interferon-stimulated genes. Approved for chronic granulomatous disease. First approved in 1999.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTIMMUNE (Interferon Gamma-1B) is a recombinant interferon gamma product administered as a subcutaneous injection, approved by the FDA on February 25, 1999. It functions as a Type 2 interferon that binds to a distinct cell surface receptor, enhancing macrophage oxidative metabolism, antibody-dependent cellular cytotoxicity (ADCC), natural killer cell activation, and expression of Fc receptors and major histocompatibility antigens. ACTIMMUNE is indicated for chronic granulomatous disease (CGD) and severe malignant osteopetrosis (SMO), rare inherited disorders affecting immune function and bone metabolism, respectively.
$0.0BPart D
Mechanism of Action
interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind…
Pharmacologic Class:
Interferon gamma
Worked on ACTIMMUNE at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.